Watch now as Jana Remlinger, MSc, discusses her recent research into a novel therapeutic approach for myelin oligodendrocyte glycoprotein antibody associated disorder (MOGAD).
MOGAD is a rare central nervous system disorder characterized by the presence of anti-MOG antibodies resulting in demyelination of the spinal cord, optic nerves, and brain. Despite similarities with multiple sclerosis and neuromyelitis optica spectrum disorder, MOGAD has recently been recognized as a distinct entity.
A potential treatment strategy for MOGAD is to reduce circulating IgG levels through interference with the IgG recycling pathway mediated by the neonatal Fc receptor (FcRn). Although the optic nerve is often detrimentally affected in MOGAD, the effect of FcRn blockade on the visual pathway has not been assessed.
To address this, Jana Remlinger and her team investigated how visual acuity is affected by a monoclonal anti-FcRn antibody treatment in a mouse model of MOGAD and found that visual function was preserved after anti-FcRn treatment. In this webinar, Jana Remlinger discusses MOG-IgG-associated neurological disorders, IgG metabolism and circulation, and the relevance of assessing visual acuity when studying autoimmune demyelinating diseases.
Key Topics Include:
- Background on MOGAD and MOG-IgG-augmented experimental autoimmune encephalomyelitis (EAE)
- Important aspects of IgG metabolism in circulation
- Relevance of targeting the neonatal FcRn when treating antibody-mediated diseases
- Importance of the visual system in MOGAD and MOG-IgG augmented EAE
- How visual acuity can be measured in such diseases
Who Should Attend?
Researchers interested in neuroimmunological disorders, vision science and measuring visual acuity, demyelinating diseases, and aging.
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Bern University Hospital